
OPKO Health (OPK) Stock Forecast & Price Target
OPKO Health (OPK) Analyst Ratings
Bulls say
OPKO Health's strategic focus on its drug development capabilities is expected to enhance its financial health, particularly by improving its balance sheet following recent transactions. The company reported a cash position that has been strengthened and achieved revenue growth of 0.9% year-over-year in 4Q24, with total revenue reaching $183.6 million, which exceeded projections. Additionally, the implementation of cost-reduction measures at BioReference and an anticipated path towards profitability by 2025 further supports a positive outlook for OPKO Health's financial performance.
Bears say
OPKO Health Inc. reported a significant decline in key revenue streams, with Diagnostics services revenue dropping 17% year-over-year to $103.1 million, driven by reduced clinical test volumes following the sale of certain BioReference assets. For the full year 2024, total revenue decreased by 17% to $713.1 million, while pharmaceutical products revenue fell by 13% to $37.4 million, largely due to adverse foreign currency exchange fluctuations. The company's outlook is further clouded by multiple risks, including underperformance in diagnostics services growth, challenges in securing regulatory approval for new pharmaceuticals, and considerable volatility in foreign exchange rates.
This aggregate rating is based on analysts' research of OPKO Health and is not a guaranteed prediction by Public.com or investment advice.
OPKO Health (OPK) Analyst Forecast & Price Prediction
Start investing in OPKO Health (OPK)
Order type
Buy in
Order amount
Est. shares
0 shares